Journal
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
Volume 50, Issue 4, Pages 1560-1573Publisher
KARGER
DOI: 10.1159/000494654
Keywords
Immunosuppression; Immunoregulation; Lupus nephritis; Mangiferin; Treg
Categories
Funding
- National Natural Science Foundation of China [81803821]
- PhD Start-up fund of Natural Science Foundation of Guangdong Province [2017A030310127]
- Guangdong Provincial Department of Science & Technology and Guangdong Provincial Academy of Chinese Medical Sciences [2014A020221053]
- Innovative and Enhancement Research Program of Guangzhou University of Chinese Medicine [E1-KFD015181K36, E1-KFD015181K37]
Ask authors/readers for more resources
Background/Aims: Lupus nephritis (LN) is an autoimmune glomerulonephritis that frequently develops secondary to systemic lupus erythematosus. Patients with LN require extensive treatments with global immunosuppressive agents. However, long-term treatment with conventional immunosuppressants may cause various side effects. Therefore, it's important to seek alternative drugs for treating LN. Here we aimed to investigate the immunoregulatory effects of mangiferin (MG), an ingredient that was originally extracted from natural herbs, including Mangifera Indica Linn. and Rhizoma Anemarrhenae. Methods: FasL-deficient B6/gld mice were used as a spontaneous LN model. The serum anti-dsDNA Ab and creatinine levels were analyzed via ELISA. Renal histology and immunopathology were determined using H&E and PAS staining, immunofluorescence (IgG and C3), and IHC staining (CD3 and alpha-SMA). Cytokine gene expression was measured by RT-PCR assays while effector T cells and Tregs were enumerated by flow analysis. Finally, the proliferation and apoptosis of T cells were measured by CFSE staining and flow analysis while their mTOR signaling was detected through Western blotting. Results: We found that administration of MG ameliorated LN in lupusprone B6/gld mice by reducing the urinary protein and serum creatinine levels, diminishing T cell infiltration in kidneys and improving renal immunopathology. MG also significantly lowered the percentages of CD44(high)CD62L(low) effector T cells in B6/gld mice. Importantly, treatments with MG augmented CD4(+) FoxP3(+) Treg frequencies in spleens, lymph nodes and kidneys of B6/gld mice. It also induced CD4(+) FoxP3(+) Tregs from CD3(+) T cells in vitro and promoted Treg proliferation. Furthermore, it inhibited CD3(+) T cell proliferation in vitro and suppressed their phosphorylation of mTOR and its downstream P70S6K. However, MG did not promote T cell apoptosis, implying that it is not cytotoxic. Depletion of CD4(+)CD25(+)FoxP3(+) Tregs in B6/gld mice abrogated its therapeutic effects on LN. Conclusion: MG exerts a novel therapeutic effect on murine LN via upregulating CD4(+)FoxP3(+) Tregs, downregulating mTOR/p70S6K pathway and improving renal immunopathology. It may be useful for treating LN in clinic. (c) 2018 The Author(s) Published by S. Karger AG, Basel
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available